<DOC>
	<DOCNO>NCT01214096</DOCNO>
	<brief_summary>Evaluate Efficacy Safety Recombinant Human Neuregulin-1 Subcutaneous Administration Patients With Chronic Systolic Heart Failure</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety Recombinant Human Neuregulin-1 Subcutaneous Administration Patients With Chronic Systolic Heart Failure</brief_title>
	<detailed_description>1 . Subcutaneous Administration NRG-1 well tolerate CHF patient 2 . Subcutaneous Administration NRG-1 improve cardiac function CHF patient 3 . Assessment relative bioavailability NRG-1 Subcutaneous Administration</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<criteria>1 . Age : 1875 year old , limitation gender ; 2 . Left ventricular ejection fraction ( LVEF ) ≤ 40 % ( ECHO ) ; 3 . Patients chronic heart failure ( NYHA class II III ) ; 4 . In past one month , clinical condition ( include history , clinical symptom sign ) relatively stable ; 5 . Patients standard treatment chronic heart failure target dose maximum tolerance dose 1 month , unchanged dose last 1 month ; 6 . Understand sign inform consent form ; 1 . Atrial fibrillation ; 2 . Subject underwent cardiac pacemaker treatment ; 3 . Subject underwent metal graft treatment ; 4 . Claustrophobia ; 5 . Acute myocardial infarction , cardiac ischemia indicate 6minute walk test , hypertrophic cardiomyopathy , constrictive pericarditis , significant valve disease congenital heart disease , severe pulmonary hypertension ; 6 . Ischemic heart failure without revascularization undergone revascularization within last 6 month ; 7 . Subject underwent cardiac surgery cerebrovascular event within previous six month ; 8 . Subjects plan cardiac transplantation ; 9 . Severe hepatic renal insufficiency ( serum creatinine &gt; 2.0 mg /dl , AST ALT five time higher upper limit normal range ) ; 10 . Subject need mechanical ventilation ; 11 . Systolic blood pressure &lt; 90mmHg , &gt; 160mmHg ; 12 . Chronic heart failure complicate acute hemodynamic disturbance acute decompensation within last 1 month ; 13 . Mobitz Type II III° atrial ventricular block，severe ventricular arrhythmia ( polymorphic frequent premature ventricular beat , frequent nonsustained ventricular tachycardia ) ; 14 . Serum potassium &lt; 3.2mmol/L , &gt; 5.5mmol/L ; 15 . Female subject pregnant plan become pregnant 16 . Childbearingaged female subject unmarried dose bear child ; 17 . Subject life expectancy le 6 month assess investigator ; 18 . Subject participate clinical trial within previous three month ; 19 . Subject previous history tumor , current tumor patient , subject precancerous disease manifest pathological examination ( ductal carcinoma situ cervical epithelial dysplasia ) 20 . Examinations ( physical examination , Xray examination , typeB ultrasonic detection method ) reveal subject malignant mass , gland hyperplasia adenoma endocrine activity , impact heart , endocrine function ( pheochromocytoma , thyroid enlargement ) ; 21 . The Investigator deem whatever reason subject likely complete study comply study procedure ( due administration reason ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Chronic Heart failure</keyword>
	<keyword>rhNRG-1</keyword>
	<keyword>MRI</keyword>
</DOC>